- Home
- LPCN vs XGN Comparison
LPCN vs XGN Comparison
Compare LPCN & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LPCN | XGN |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.8M | 65.9M |
| IPO Year | 2011 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LPCN | XGN |
|---|---|---|
| Price | $2.36 | $2.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $8.86 |
| AVG Volume (30 Days) | ★ 874.4K | 175.4K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 46.18 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,976,677.00 | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | $92.00 | $13.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $2.59 |
| 52 Week High | $12.37 | $12.23 |
Technical Indicators
Market Signals| Indicator | LPCN | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 32.51 | 44.42 |
| Support Level | $1.81 | $2.59 |
| Resistance Level | $3.55 | $3.29 |
| Average True Range (ATR) | 0.17 | 0.16 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 48.90 | 37.10 |
Price Performance
Historical ComparisonAbout LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About XGN Exagen Inc.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.